Vetr cut shares of Celgene Corp. (NASDAQ:CELG) from a buy rating to a hold rating in a report published on Monday. They currently have $125.81 price objective on the biopharmaceutical company’s stock.

CELG has been the subject of a number of other reports. Canaccord Genuity set a $156.00 price target on Celgene Corp. and gave the company a buy rating in a research report on Sunday, September 18th. Leerink Swann reaffirmed a market perform rating and set a $135.00 price target on shares of Celgene Corp. in a research report on Monday, September 12th. Morgan Stanley reaffirmed a hold rating and set a $120.00 price target on shares of Celgene Corp. in a research report on Wednesday, August 3rd. Cowen and Company reaffirmed a buy rating and set a $150.00 price target on shares of Celgene Corp. in a research report on Wednesday, August 10th. Finally, Jefferies Group reaffirmed a buy rating and set a $137.00 price target on shares of Celgene Corp. in a research report on Tuesday, August 9th. Four equities research analysts have rated the stock with a hold rating and twenty-six have given a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $136.46.

Analyst Recommendations for Celgene Corp. (NASDAQ:CELG)

Shares of Celgene Corp. (NASDAQ:CELG) opened at 120.30 on Monday. The company has a 50-day moving average price of $108.88 and a 200 day moving average price of $106.73. The company has a market capitalization of $93.26 billion, a P/E ratio of 45.69 and a beta of 1.71. Celgene Corp. has a 1-year low of $93.05 and a 1-year high of $127.00.

Celgene Corp. (NASDAQ:CELG) last posted its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.48 by $0.10. Celgene Corp. had a return on equity of 70.48% and a net margin of 19.71%. The company had revenue of $2.98 billion for the quarter, compared to analyst estimates of $2.84 billion. During the same quarter last year, the company earned $1.23 earnings per share. The company’s revenue for the quarter was up 27.8% on a year-over-year basis. Equities research analysts anticipate that Celgene Corp. will post $5.92 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the propert of of Daily Political. If you are viewing this story on another website, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be read at http://www.dailypolitical.com/2016/11/29/celgene-corp-celg-lowered-to-hold-at-vetr-inc.html.

In other news, major shareholder Corp /De/ Celgene bought 800,150 shares of Celgene Corp. stock in a transaction on Monday, October 24th. The shares were purchased at an average price of $14.00 per share, for a total transaction of $11,202,100.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Michael A. Friedman sold 18,600 shares of the company’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $116.10, for a total value of $2,159,460.00. Following the transaction, the director now owns 18,600 shares in the company, valued at approximately $2,159,460. The disclosure for this sale can be found here. Company insiders own 0.97% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of CELG. First Financial Corp IN increased its position in Celgene Corp. by 30.9% in the third quarter. First Financial Corp IN now owns 967 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 228 shares during the period. Jolley Asset Management LLC increased its position in Celgene Corp. by 58.8% in the second quarter. Jolley Asset Management LLC now owns 1,215 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 450 shares during the period. Smithfield Trust Co. increased its position in Celgene Corp. by 12.5% in the second quarter. Smithfield Trust Co. now owns 1,282 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 142 shares during the period. Cornerstone Advisors Inc. increased its position in Celgene Corp. by 202.8% in the third quarter. Cornerstone Advisors Inc. now owns 1,320 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 884 shares during the period. Finally, Integrated Investment Consultants LLC increased its position in Celgene Corp. by 21.8% in the second quarter. Integrated Investment Consultants LLC now owns 1,339 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 240 shares during the period. Hedge funds and other institutional investors own 76.43% of the company’s stock.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

To view Vetr’s full report, visit Vetr’s official website.

Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with MarketBeat.com's FREE daily email newsletter.